Objective: To verify whether absolute monocyte count (AMC) and lymphocyte- monocyte ratio (LMR) at diagnosis are valid prognostic parameters in classical Hodgkin lymphoma (cHL).

Patients And Methods: Data were collected from 1450 patients with cHL treated in Israel and Italy from January 1, 1988, through December 31, 2007.

Results: The median age of the patients was 33 years (range, 17-72 years), and 70% (1017) of the patients had nodular sclerosis (NS); the median follow-up duration was 87 months. The best cutoff value for AMC was 750 cells/mm(3), and the best ratio for LMR was 2.1. The adverse prognostic impact of an AMC of more than 750 cells/mm(3) was confirmed for the entire cohort, and its clinical significance was particularly evident in patients with NS histology. The progression-free survival (PFS) at 10 years for an AMC of more than 750 cells/mm(3) was 65% (56%-72%), and the PFS at 10 years for an AMC of 750 cells/mm(3) or less was 81% (76%-84%; P<.001). The overall survival (OS) at 10 years for an AMC of more than 750 cells/mm(3) was 78% (70%-85%), and the OS at 10 years for an AMC of 750 cells/mm(3) or less was 88% (84%-90%; P=.01). In multivariate analysis, both AMC and LMR maintained prognostic significance for PFS (hazard ratio [HR], 1.54, P=.006, and HR, 1.50, P=.006) after adjusting for the international prognostic score, whereas the impact on OS was confirmed (HR, 1.56; P=.04) only in patients with NS and an AMC of more than 750 cells/mm(3).

Conclusion: This study confirms that AMC has prognostic value in cHL that is particularly significant in patients with NS subtype histology. This finding links the known impact of macrophages and monocytes in Hodgkin lymphoma with routine clinical practice.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.mayocp.2015.03.025DOI Listing

Publication Analysis

Top Keywords

amc 750
16
750 cells/mm3
16
absolute monocyte
8
monocyte count
8
nodular sclerosis
8
hodgkin lymphoma
8
1450 patients
8
ratio lmr
8
pfs years
8
years amc
8

Similar Publications

Baseline Viral Load and On-treatment Hepatocellular Carcinoma Risk in Chronic Hepatitis B: A Multinational Cohort Study.

Clin Gastroenterol Hepatol

August 2024

Department of Gastroenterology, Liver Center, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea. Electronic address:

Background & Aims: Hepatocellular carcinoma (HCC) risk persists in patients with chronic hepatitis B (CHB) despite antiviral therapy. The relationship between pre-treatment baseline hepatitis B virus (HBV) viral load and HCC risk during antiviral treatment remains uncertain.

Methods: This multinational cohort study aimed to investigate the association between baseline HBV viral load and on-treatment HCC risk in 20,826 noncirrhotic, hepatitis B e antigen (HBeAg)-positive and HBeAg-negative patients with baseline HBV DNA levels ≥2000 IU/mL (3.

View Article and Find Full Text PDF
Article Synopsis
  • The study aimed to create a predictive model for post-treatment survival in hepatocellular carcinoma (HCC) patients by utilizing pre-treatment CT images alongside clinical data from 692 patients.
  • A 3D convolutional neural network (CNN) was employed to analyze CT features and incorporate patient-related factors and treatment options to estimate conditional survival probabilities over time.
  • The final model achieved high predictive performance metrics, demonstrating that combining imaging and clinical data significantly outperformed models that relied on only one type of data.
View Article and Find Full Text PDF

Objectives: Diagnostic prediction models exist to assess the probability of bacterial meningitis (BM) in paediatric patients with suspected meningitis. To evaluate the diagnostic accuracy of these models in a broad population of children suspected of a central nervous system (CNS) infection, we performed external validation.

Methods: We performed a systematic literature review in Medline to identify articles on the development, refinement or validation of a prediction model for BM, and validated these models in a prospective cohort of children aged 0-18 years old suspected of a CNS infection.

View Article and Find Full Text PDF

Characterization of Ceftriaxone-Resistant Among Korean Children.

J Korean Med Sci

April 2024

Department of Pediatrics, Asan Medical Center Children's Hospital, University of Ulsan College of Medicine, Seoul, Korea.

Article Synopsis
  • A study investigated ceftriaxone-resistant strains of a common respiratory pathogen in children at a hospital in South Korea, focusing on resistance mechanisms like changes in penicillin-binding protein 3 (PBP3) and β-lactamase production.
  • Out of 68 strains collected, 19 were identified as ceftriaxone-resistant, with most showing specific mutations in PBP3 that contributed to their resistance.
  • The research revealed that the highest levels of resistance were linked to combinations of mutations, particularly S385T and L389F, indicating a significant concern for antibiotic effectiveness in treating these infections.
View Article and Find Full Text PDF

Use of a commercial artificial intelligence-based mammography analysis software for improving breast ultrasound interpretations.

Eur Radiol

October 2024

Department of Radiology and Research Institute of Radiology, Asan Medical Center, University of Ulsan College of Medicine, 88, Olympic-Ro 43-Gil, Songpa-Gu, Seoul, 05505, South Korea.

Objectives: To evaluate the use of a commercial artificial intelligence (AI)-based mammography analysis software for improving the interpretations of breast ultrasound (US)-detected lesions.

Methods: A retrospective analysis was performed on 1109 breasts that underwent both mammography and US-guided breast biopsy. The AI software processed mammograms and provided an AI score ranging from 0 to 100 for each breast, indicating the likelihood of malignancy.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!